Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 104242 | 4.345 |
09:34 ET | 65893 | 4.305 |
09:36 ET | 8891 | 4.32 |
09:38 ET | 5920 | 4.3201 |
09:39 ET | 117467 | 4.295 |
09:41 ET | 5441 | 4.315 |
09:43 ET | 19253 | 4.305 |
09:45 ET | 8657 | 4.31 |
09:48 ET | 4586 | 4.3 |
09:50 ET | 2790 | 4.3001 |
09:52 ET | 14723 | 4.305 |
09:54 ET | 25360 | 4.305 |
09:56 ET | 14605 | 4.31 |
09:57 ET | 3635 | 4.3 |
09:59 ET | 8639 | 4.255 |
10:01 ET | 13704 | 4.27 |
10:03 ET | 7094 | 4.265 |
10:06 ET | 5936 | 4.27 |
10:08 ET | 4045 | 4.27 |
10:10 ET | 6904 | 4.285 |
10:12 ET | 34668 | 4.265 |
10:14 ET | 11393 | 4.255 |
10:15 ET | 40243 | 4.25 |
10:17 ET | 19305 | 4.245 |
10:19 ET | 3461 | 4.245 |
10:21 ET | 3428 | 4.245 |
10:24 ET | 44139 | 4.27 |
10:26 ET | 2040 | 4.27 |
10:28 ET | 3800 | 4.27 |
10:30 ET | 7142 | 4.285 |
10:32 ET | 22536 | 4.27 |
10:33 ET | 6005 | 4.27 |
10:35 ET | 1390 | 4.27 |
10:37 ET | 28906 | 4.2801 |
10:39 ET | 11335 | 4.29 |
10:42 ET | 19625 | 4.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.6B | -12.4x | --- |
Celldex Therapeutics Inc | 2.6B | -13.6x | --- |
MoonLake Immunotherapeutics | 2.7B | -56.0x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.7x | --- |
Agios Pharmaceuticals Inc | 2.5B | -6.8x | --- |
Structure Therapeutics Inc | 2.3B | -16.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 4,950.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.